Crinetics Pharmaceuticals (CRNX) to Post Earnings on Tuesday

Crinetics Pharmaceuticals (NASDAQ:CRNX) is projected to announce its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect the company to post earnings of ($1.18) per share and revenue of $14.8420 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.01). Crinetics Pharmaceuticals had a negative return on equity of 43.96% and a negative net margin of 2,747.18%.The firm had revenue of $10.73 million for the quarter, compared to analysts’ expectations of $8.51 million. During the same period last year, the company posted ($1.04) earnings per share. The business’s quarterly revenue was up 2873.4% on a year-over-year basis. On average, analysts expect Crinetics Pharmaceuticals to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Crinetics Pharmaceuticals Stock Performance

CRNX opened at $83.52 on Friday. Crinetics Pharmaceuticals has a fifty-two week low of $25.83 and a fifty-two week high of $84.00. The company has a fifty day moving average of $54.15 and a two-hundred day moving average of $46.24. The stock has a market capitalization of $8.81 billion, a price-to-earnings ratio of -16.28 and a beta of 0.23.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Lifesci Capital lowered Crinetics Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Citizens Jmp lowered Crinetics Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. TD Cowen downgraded Crinetics Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 8th. Oppenheimer reissued a “market perform” rating on shares of Crinetics Pharmaceuticals in a research note on Tuesday, July 7th. Finally, Wall Street Zen upgraded shares of Crinetics Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 12th. Five equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $81.00.

Insider Transactions at Crinetics Pharmaceuticals

In other news, Director Stephanie Okey sold 6,900 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $35.67, for a total value of $246,123.00. Following the transaction, the director directly owned 6,400 shares of the company’s stock, valued at approximately $228,288. This trade represents a 51.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Coelho Rogerio Vivaldi sold 3,000 shares of the business’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $40.00, for a total transaction of $120,000.00. Following the transaction, the director owned 19,225 shares in the company, valued at $769,000. The trade was a 13.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.80% of the stock is owned by corporate insiders.

Institutional Trading of Crinetics Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CRNX. Headlands Technologies LLC purchased a new stake in shares of Crinetics Pharmaceuticals in the 2nd quarter valued at $30,000. Smartleaf Asset Management LLC lifted its position in shares of Crinetics Pharmaceuticals by 107.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 639 shares of the company’s stock worth $30,000 after purchasing an additional 331 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Crinetics Pharmaceuticals in the second quarter valued at approximately $45,000. Parallel Advisors LLC increased its position in shares of Crinetics Pharmaceuticals by 34.6% during the fourth quarter. Parallel Advisors LLC now owns 1,225 shares of the company’s stock worth $57,000 after acquiring an additional 315 shares during the period. Finally, Arax Advisory Partners increased its position in shares of Crinetics Pharmaceuticals by 131.2% during the fourth quarter. Arax Advisory Partners now owns 1,498 shares of the company’s stock worth $70,000 after acquiring an additional 850 shares during the period. Hedge funds and other institutional investors own 98.51% of the company’s stock.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.